Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide

Chen, Ling-YaLing-YaChenHSIN-YUN SUNYU-CHUNG CHUANGYU-SHAN HUANGWANG-DA LIUKUAN-YIN LINChang, Hsi-YenHsi-YenChangLuo, Yu-ZhenYu-ZhenLuoWu, Pei-YingPei-YingWuSu, Yi-ChingYi-ChingSuLiu, Wen-ChunWen-ChunLiuCHIEN-CHING HUNG2023-05-032023-05-032023-02-0916841182https://scholars.lib.ntu.edu.tw/handle/123456789/630701While some evidence has suggested the benefits of co-formulated bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) in improving the quality of life of people living with HIV (PLWH), patient-reported outcome studies that focus on Asian population remain scarce. We aimed to determine the changes in HIV-related symptom burden in virally-suppressed PLWH switching to B/F/TAF in a real-world setting.enAdverse effect; HIV Symptom index; Integrase strand-transfer inhibitor; Quality of life; Viral suppressionPatient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamidejournal article10.1016/j.jmii.2023.01.015368063642-s2.0-85150351802https://api.elsevier.com/content/abstract/scopus_id/85150351802